v3.26.1
Consolidated Statements of Cash Flows
€ in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (4,156) $ (5,347)
Adjustments required to reconcile net loss for the year to net cash used in operating activities:    
Depreciation and amortization 71 18
Issuance of shares to employees and service providers 2,054 746
Share based compensation to employees and directors 91 1
Expenses funded by non-controlling interests 80
Gain from sales of property and equipment (3) [1]
Gain from standby equity purchase agreement II (note 15(7)) (1,811) (428)
Expenses from standby equity purchase agreement II (note 15(7)) 182 170
Interest in respect of loans 47 16
Gain from deconsolidation of subsidiary (44)
Change in fair value of warrant liability (234) 5
Change in fair value of credit facility liability 62
Change in fair value of PIPE’s warrant liability 1,382
Change in fair value of investment in nonconsolidated affiliate 603 1,299
Change in fair value of convertible loan (46) 56
Change in fair value of solar project (919) (44)
Change in fair value of marketable securities 68 (88)
Change in fair value of contingent considerations (1,136)
Exchange rate differences on operating leases 3 9
Decrease (increase) in accounts receivable, net 9 (36)
Decrease in inventory 7 101
Decrease in prepaid expenses and other current assets 66 262
Increase (decrease) in accounts payable (20) 12
Decrease in other liabilities (164) (169)
Decrease in operating lease expense 14 48
Change in operating lease liability (14) (50)
Net cash used in operating activities (3,808) (3,419)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Investment in solar projects under development (743) (250)
Proceeds from sales of property and equipment 3 [1]
Purchase of property (14)
Proceeds from sale of subsidiary (net of cash disposed) (25)
Cash used in purchased of MitoCareX (565)
Long term loan granted (406)
Investment in marketable securities (219)
Short term loan granted (872) (250)
Solar photovoltaic joint venture project (1,017) (764)
Net cash used in investing activities (3,233) (1,889)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from credit facility 1,340
Repayment of credit facility (1,165)
Proceeds from PIPE Agreement 1,500
Proceeds from exercise of warrants from PIPE Agreement 1,830
Proceeds from promissory note 1,500 1,455
Repayments of promissory note (300) (1,543)
Proceeds from standby equity purchase agreement, net 4,151 3,135
Net cash provided by financing activities 8,856 3,047
Effect of exchange rate changes on cash and cash equivalents (11) (8)
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH 1,804 (2,269)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF YEAR 2,209 4,478
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF YEAR 4,013 2,209
Supplemental disclosure of cash flow information:    
Cash and cash equivalents 3,832 1,923
Restricted cash 37
Cash classified as assets of discontinued operations 31
Cash classified as assets held for sale 144 255
Total cash, cash equivalents and restricted cash 4,013 2,209
Cash paid during the year for:    
Interest 77
Non cash transactions:    
Initial recognition of operating lease liability and a corresponding right-of- use asset 39
Reclassification of warrant liabilities to equity upon exercise of warrants 2,769
Issuance of shares for future services 1,107 12
Non-cash financing costs related to issuance of promissory note 409
Recognition of Prepaid Warrant Costs and Corresponding Warrant Liability $ 307
[1] Less than $1 thousand.